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Background: Estrogens may prevent cognitive de-
cline and Alzheimer disease. Animal study findings
have shown beneficial effects of estrogen on the brain,
particularly on the hippocampus, a structure rela-
ted to memory performance and early Alzheimer
disease.
Objective: To investigate whether higher levels of
endogenous estradiol in older women and men are as-
sociated with larger hippocampal volumes on mag-
netic resonance imaging and better memory perfor-
mance.
Design and Setting: Cross-sectional analysis within
the Rotterdam Scan Study, a population-based study in
the Netherlands of elderly subjects who do not have de-
mentia.
Participants: Two hundred ten women and 202 men,
aged 60 to 90 years, with plasma levels of total estradiol
and, in part, 162 women and 149 men also with levels
of bioavailable and free estradiol.
Main Outcome Measure: Hippocampal volumes on
magnetic resonance imaging and memory performance
(delayed recall).
Results: Women with higher total estradiol levels had
smaller hippocampal volumes and poorer memory perfor-
mance −0.29 mL (95% confidence interval, –0.57 to –0.00)
and –0.4 (95% confidence interval, −1.3 to 0.5) fewer words
in delayed recall testing for the highest tertile compared
with the lowest tertile. Similar inverse associations were
found among bioavailable and free estradiol levels, hippo-
campal volumes, and memory. In men, no association was
observed between estradiol levels and hippocampal vol-
ume, but a trend was found for higher levels of total estra-
diol to be associated with poorer memory performance.
Conclusion:Our data do not support the hypothesis that
higher levels of endogenous estradiol in older women and
men are associated with larger hippocampal volumes and
better memory performance.
Arch Neurol. 2003;60:213-220
A FTER MENOPAUSE, womenhave low levels of circulat-ing estrogens. Observa-tional studies reported a re-duced risk of cognitive
decline and Alzheimer disease (AD) in post-
menopausal women using estrogen replace-
ment therapy.1,2 In animals, estrogens pro-
tect hippocampal neurons exposed to
amyloid,3 improve synapse formation on
dendritic spines in the hippocampus,4 and
promote survival of hippocampal neu-
rons, acting in concert with growth fac-
tors.5 Estrogen receptors are located
throughout the brain, but especially in the
hippocampus.6 Given the beneficial effects
of estrogens on the hippocampus in ani-
mals, it has been hypothesized that estro-
gens may prevent hippocampal atrophy, a
key feature of AD.7 The hippocampus plays
a pivotal role in memory function and is one
of the first regions affected in AD.8 The aim
of this study was to investigate whether
higher endogenous levels of estradiol were
associated with larger hippocampal vol-
umes on magnetic resonance imaging (MRI)
and better memory performance. We ex-
amined this hypothesis in a population-
based study of older women and men who
did not have dementia.
METHODS
ROTTERDAM SCAN STUDY
This study is based on all participants in the
Rotterdam Scan Study that originated from the
Rotterdam Study. The Rotterdam Study is a
large population-based cohort study in the
Netherlands that started in 1990 and investi-
gates the prevalence, incidence, and determi-
nants of various chronic diseses among el-
derly participants.9 From 1995 to 1996, we
randomly selected 965 living members (aged,
60-90 years) of this cohort in strata of sex and
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age (5 years) for participation in the Rotterdam Scan Study.10After
exclusion of individuals who had dementia (n=16),11 or had
contraindications to undergo MRI (n=117), 832 persons were
eligible for our study. Among these, 563 participants gave their
written informed consent to participate in the study (response
rate, 68%), which included undergoing an MRI brain scan. The
study was approved by the medical ethics committee of Eras-
mus MC, Rotterdam, the Netherlands.
MRI PROCEDURES
All subjects underwent T1-, T2-, and proton-density–
weighted images in a 1.5-T magnetic resonance unit (VISION
MR; Siemens, Erlangen, Germany).12 For volumetric measure-
ments of the hippocampus, a custom-made, inversion recovery–
double-contrast, 3-dimensional, half-Fourier acquisition single-
shot turbo spin-echo (HASTE) sequence was included (inversion
time, 440 milliseconds; repetition time, 2800 milliseconds; 128
contiguous sagittal slices of 1.2 mm; acquisition matrix,
192256 pixels; and field of view, 256256 cm). Two HASTE
modules were sequentially acquired after the inversion pulse
(effective echo times of 29 milliseconds and 440 milliseconds).
Each HASTE module combined nonselective radiofrequency
excitations to provide a short interecho spacing of 3.9 milli-
seconds. The first HASTE module was used for the hippocam-
pal volume measurement.
HIPPOCAMPAL VOLUMES
We reconstructed a series of coronal brain slices (contiguous
1.5-mm slices) based on the HASTE sequence, aligned to be
perpendicular to the long axis of the hippocampus. All recon-
structed slices were transferred to a workstation (Magic View
1000; Siemens) for volumetric assessment of the left and right
hippocampi (Figure 1). Referencing to an anatomical atlas,13
we manually traced the boundaries of both hippocampi on each
slice using a mouse-driven pointer. We proceeded from pos-
terior to anterior, starting on the slice where the crux of the
fornices was in full profile. The alveus could often be used to
delineate the boundary of the hippocampal head from the amyg-
dala. Entering the outlined surface areas (expressed in milli-
meters squared), we multiplied the summed surface areas on
each side with slice thickness to yield estimates of the left and
right hippocampal volume (expressed in milliliters). In the cur-
rent analyses the left and right hippocampal volumes were
summed.
We also reconstructed a midsagittal slice (thickness 3.0
mm). The midsagittal area, which was used as a proxy for in-
tracranial volume, was measured by tracing the inner table of
the skull. Two raters (T.d.H. and a colleague), who were blinded
to any clinical information related to the participants, as-
sessed the scans. Studies performed on 14 random scans to evalu-
ate intrarater and interrater correlation showed good overall
agreement.
MEMORY PERFORMANCE
All participants underwent neuropsychological testing.12 The
Mini-Mental State Examination was administered to assess global
cognitive function.14 Memory function was evaluated by a 15-
word learning test based on the Rey Auditory Verbal Learning
Test.15 This test consists of 3 learning trials in which 15 words
have to be remembered. After 15 minutes, the subject is asked
to recall as many words as possible (delayed recall). In the pres-
ent study we used the delayed recall score because this score is
most strongly associated with hippocampal volumes16 and with
early AD.17
BLOOD MEASUREMENTS
Venipuncture was done in nonfasting subjects between 8:30
AM and 4 PM at baseline examination of the Rotterdam Study
(1990-1993). Blood samples were collected in 5-mL tubes con-
taining a 0.5-mL sodium citrate solution. All tubes were stored
on ice before and after blood sampling. Platelet-free plasma was
obtained by 2-stage centrifugation (10 minutes at 1600g at 4°C
and 30 minutes at 7000g at 4°C). Platelet-free samples were im-
mediately frozen in liquid nitrogen and stored at −80°C. As-
says were performed blinded to information on the subject.
Plasma levels of estradiol and sex hormone–binding globulin
were estimated with double antibody radioimmunoassays (ul-
trasensitive method for estradiol; Diagnostic Systems Labora-
tories, Webster, Tex). Because of the small volumes of plasma
available, all estradiol levels are single-sample estimations. Intra-
assay coefficients of variation, determined on the basis of du-
plicate results of internal quality control pools with 3 different
levels of each analyte, were below 4% for sex hormone–
binding globulin and 18% for estradiol. Because interassay varia-
tions were 14% (sex hormone–binding globulin) and 21% (es-
tradiol), results of all batches were normalized by multiplying
all concentrations within a batch with a factor, which equal-
ized results for the internal quality control pools. As measures
of the levels of bioavailable and free estradiol, nonsex hormone–
binding globulin-bound estradiol, and nonprotein-bound es-
tradiol, respectively, were calculated on the basis of hormone
and binding protein levels.18,19 The median interval from blood
sampling (1990-1993) to hippocampal volumes and memory
testing (1995-1996) was 2.9 years (range, 1.6-6.6 years).
COVARIATES
Several variables may confound an association between estra-
diol levels and hippocampal volume or memory performance,
such as age at the time of venipuncture, educational level, smok-
ing habits, alcohol intake, body mass index (BMI) (calculated
as weight in kilograms divided by the height in meters squared),
depressive symptoms, and apolipoprotein E APOE genotype;
and for women, the variables included type of menopause, age
at menopause, and use of hormone replacement therapy (HRT)
H H
Figure 1. Coronal slice on which the left and right hippocampi (H) are
depicted.
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(ie, those who ever used HRT or those who never used HRT)
for menopausal reports (Anatomical Therapeutical Chemical
code g03). The level of education was dichotomized into pri-
mary education and lower vocational training and university
education. We categorized smoking status into current, former,
and never and made dummy variables for the analyses. Alco-
hol intake was recorded in grams per day.22 Depressive symp-
toms were assessed using the Center for Epidemiologic Studies–
Depression Scale (CES-D)23 at the time of assessment of memory
performance. Apolipoprotein E genotyping was done accord-
ing to standard methods24 and was coded into non-APOE 4
carrier and APOE 4 carrier. Type of menopause was classified
into natural or artificial (surgically or chemically induced). Age
at natural menopause was defined as the age at which menses
had not occurred for at least 1 year. Type and age of meno-
pause were combined in 1 categorical variable with 4 groups:
(1) artificial menopause, (2) natural menopause before the age
of 48 years, (3) natural menopause between ages 48 and 52 years,
or (4) natural menopause after the age of 52 years.
STUDY SAMPLE
To obtain the study samples for the analyses, we excluded 4
women who used HRT at the time of blood drawing, leaving
559 subjects (Figure 2). Because estradiol levels were mea-
sured as part of several blood measurements and small amounts
of plasma were available, we randomly missed total estradiol
levels for 147 subjects. Thus, 412 subjects for the analyses on
total estradiol levels were included. Because of missing data on
binding protein levels (n=101), we had bioavailable and free
estradiol levels in 311 subjects. These 311 subjects with bio-
available and free estradiol levels were similar to the 248 sub-
jects who were dropped from these analyses for age, hippo-
campal volume, and delayed recall score.
DATA ANALYSIS
All analyses were performed in women and men separately. We
first investigated whether there was a threshold in the relation
between estradiol level and outcome by analysis of covariance
(ANCOVA). Tertiles of total, bioavailable, and free estradiol were
the group variable and we calculated adjusted mean hippo-
campal volumes and delayed recall scores in each tertile. Three
consecutive models were used. The first adjusted for age and—in
the hippocampal analyses—midsagittal area to account for in-
tracranial volume.25 After separately investigating several co-
variates, it appeared as if the BMI was the strongest con-
founder in the associations so the second model was adjusted,
in addition to age and midsagittal area, for BMI. In the third
model we additionally entered educational level, smoking, al-
cohol use, CES-D score, APOE genotype, and, for women, age
at menopause, type of menopause, and ever taking HRT. Be-
cause the ANCOVA did not suggest a specific threshold in the
relation between estradiol levels and outcome, we performed
a multivariate linear regression analysis to calculate the differ-
ence in hippocampal volume and delayed recall score per SD
increase in estrogen levels. To investigate whether there was
an indication of differential associations in age strata (70 years
and 70 years) or APOE genotype, we included in the multi-
variate linear model an interaction term and performed strati-
fied analyses. Finally, we repeated the analyses excluding women
with a history of HRT use.
RESULTS
Of the 210 women and 202 men with total estradiol mea-
surements, 24 women and 16 men had no hippocampal
volume assessment (because they developed claustro-
phobia during the MRI) and 6 women and 8 men had
no reliable delayed recall data (mostly owing to motiva-
tional problems). Characteristics of the study sample are
given in Table 1. There were no differences in the char-
acteristics between subjects with total estradiol levels and
subjects without total estradiol levels. Estradiol levels of
women were lower than those of men, reflecting the fact
that women were postmenopausal and were not taking
HRT at the time of venipuncture.
In women, estradiol levels were negatively corre-
lated with age and positively correlated with BMI. In men,
estradiol levels were negatively correlated with age and
positively correlated with alcohol intake and CES-D score
(Table 2). Hippocampal volumes and delayed recall
scores decreased with increasing age (both in women and
men, −0.03 mL/y and −0.1 words per year).
WOMEN
Estradiol Level and Hippocampal Volume
In women, the age- and midsagittal-adjusted mean (SE)
hippocampal volumes decreased across higher tertiles of
total estradiol levels from 6.24 (0.10) mL to 6.22 (0.10)
mL to 6.07 (0.10) mL, but there were no significant dif-
ferences between tertiles. When the BMI was included
as a covariate, the mean (SE) hippocampal volumes were
6.28 (0.10) mL, 6.21 (0.10) mL, and 6.04 (0.10) mL, re-
spectively, but differences were again not statistically sig-
nificant. Figure 3A shows that after additional adjust-
ments for all other covariates the negative association
between the total estradiol level and hippocampal vol-
ume became statistically significant (difference between
the highest and lowest tertile of total estradiol −0.29 mL
[95% confidence interval (CI), −0.57 to −0.00]). When
we analyzed the total estradiol level as a continuous mea-
sure, we found a nonsignificant decrease in hippocam-
pal volume per SD increase in total estradiol level
(Table 3). There was a nonsignificant inverse relation
between the bioavailable estradiol level and hippocam-
pal volumes; the age- and midsagittal-adjusted means of
hippocampal volume across higher bioavailable estra-
diol tertiles was 6.22 (0.12) mL, 6.17 (0.11) mL, and 6.00
563 (281 Women and 282 Men)
Assessed for Eligibility
From the Rotterdam Scan Study
559 (277 Women and 282 Men)
Studied
4 Women Excluded Owing to
Current HRT
147 (67 Women and 80 Men)
Missing Estradiol Level Data
101 (48 Women and 53 Men)
With Missing Binding Protein
Level Data
412 (210 Women and 202 Men)
With Total Estradiol
Level Data
311 (162 Women and 149 Men)
With Bioavailable and Free
Estradiol Level Data
Figure 2. Description of study sample. HRT indicates hormone replacement
therapy.
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(0.11) mL. When the BMI was included in the model, a
significant smaller hippocampal volume was found in
women with bioavailable estradiol levels in the highest
tertile of bioavailable estradiol compared with the low-
est tertile (difference, −0.37 mL [95% CI, −0.71 to −0.03]).
Additional adjustments did not change this inverse re-
lation (Figure 3A). When we analyzed bioavailable es-
tradiol levels as a continuous measure, we found a non-
significant decrease of hippocampal volume of −0.09 mL
(95% CI, −0.25 to 0.06) per SD (10-pmol/L) increase. The
relation between free estradiol levels and hippocampal
volumes was similar to that of bioavailable estradiol lev-
els (Figure 3A). The inverse associations between estra-
diol levels and hippocampal volumes were primarily seen
in the oldest age group (in age70 years: per SD in-
crease in total estradiol level the fully adjusted differ-
ence in hippocampal volumes was 0.07 mL [95% CI, −0.09
to 0.23]; in age70 years: −0.24 mL [95% CI, −0.44 to
−0.04]; P of interaction term .04). The negative associa-
tions between estradiol level and hippocampal volumes
were more pronounced in APOE 4 carriers than in non-
APOE 4 carriers, although the interaction term was not
statistically significant (Table 4).
Estradiol Level and Memory
The age-adjusted delayed recall score decreased nonsig-
nificantly across total estradiol tertiles from 6.5 ( 0.3) to
6.1 (0.3) to 6.1 (0.3) words. Figure 3B shows that addi-
tional adjustments for other covariates did not substan-
tially change these results. The fully adjusted difference
in delayed recall words between the highest and lowest
tertile of total estradiol levels was −0.4 (95% CI, −1.3 to
0.5). When we analyzed the total estradiol level as a con-









Age, mean (SD), y 70 (8) 69 (8) 71 (8)
BMI, mean (SD), kg/m2 26.8 (3.9) 26.1 (2.9) 26.3 (3.2)
Subjects with a primary education, % 37 23 34
Subjects currently smoking, % 16 24 23
Alcohol consumption, mean (SD), g/d 7.6 (11.5) 17.4 (10.9) 13.7 (17.0)
CES-D scale score, mean (SD) 7.0 (6.6) 4.6 (5.3) 5.0 (5.7)
APOE genotype, % APOE 4 carrier 27 32 27
MMSE score, mean (SD) 27.6 (2.3) 27.8 (2.1) 27.7 (2.0)
Total estradiol level, median (range), pg/mL 3.7 (0.0-17.7) 12.3 (0.0-42.8) NA
Bioavailable estradiol level, median (range), pg/mL* 2.4 (0.0-13.4) 9.3 (0.0-32.7) NA
Free estradiol level, median (range), pg/mL* 0.09 (0.00-0.47) 0.33 (0.00-1.14) NA
Midsagittal area, mean (SD), cm2† 143.1 (8.8) 155.2 (9.9) 149.3 (11.1)
Hippocampus, mean (SD), mL† 6.17 (0.81) 6.59 (0.89) 6.36 (0.88)
Delayed recall score, mean (SD), No. of words‡ 6.2 (2.8) 5.5 (2.4) 5.4 (2.6)
Abbreviations: APOE, apolipoprotein E; BMI, body mass index; CES-D, Center for Epidemiologic Studies–Depression Scale; HRT, hormone replacement therapy;
MMSE, Mini-Mental State Examination; NA, not available.
To convert estradiol values to pmol/L, multiply by 3.67.
*Values were available for 162 women and 149 men.
†Values were available for 186 women and 186 men.
‡Values were available for 204 women and 194 men. Higher scores reflect better performance.
Table 2. Correlations Between Several Continuous Variables in 210 Women and in 202 Men*
Variable Total Estradiol Level Age Educational Level BMI Alcohol Consumption CES-D Scale
Age, per year −0.49† . . .‡ . . . . . . . . . . . .
−0.62† . . . . . . . . . . . . . . .
Education, per grade −0.08 −1.02† . . . . . . . . . . . .
−0.87 −0.22 . . . . . . . . . . . .
BMI, kg/m2 0.97† 0.24 −0.05† . . . . . . . . .
1.04 0.04 −0.06 . . . . . . . . .
Alcohol consumption, per g/d 0.01 −0.13† 0.01 −0.03 . . . . . .
0.33† −0.04 −0.00 0.02 . . . . . .
CES-D score, per point −0.27 0.20† −0.02 −0.04 0.02 . . .
0.77† −0.05 0.02 0.03 0.20 . . .
Midsagittal area, per cm2 0.23 −0.22† 0.02† 0.01 −0.05 −0.10†
0.14 −0.07 0.02 −0.01 −0.11 0.05
Abbreviations: BMI, body mass index; CES-D, Center for Epidemiologic Studies–Depression Scale.
*Values are unadjusted regression coefficients in women and men (italics). The variables in the upper row are dependent variables.
†P.05.
‡Ellipses indicate not applicable.
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tinuous measure, we found a nonsignificant decrease in
delayed recall words (Table 3). There was a significant
inverse relation between bioavailable estradiol tertiles and
delayed recall (Figure 3B), although when we analyzed
bioavailable estradiol levels continuously, we found a non-
significant decrease in delayed recall words of −0.2 (95%
CI, −0.7 to 0.2) per SD increase. The results were simi-
lar for the relation between the free estradiol level and
delayed recall score (Figure 3B). Again, the inverse as-
sociations between the estradiol level and memory were
stronger in the oldest age groups (data not shown). The
associations were not different in APOE 4 strata (Table
4). Exclusion of women who had used HRT in the past
(n=17) did not change any of the above results.
MEN
Estradiol Level and Hippocampal Volume
In men, there was no association between estradiol lev-
els and hippocampal volumes (age and midsagittal-
adjusted hippocampal volumes in total estradiol ter-
tiles: 6.55 [0.11] mL, 6.68 [0.11] mL, and 6.52 [0.11])
mL). Additional adjustments for the other covariates did
not change these estimates (Figure 3C and Table 3). There
was also no association between bioavailable or free
estradiol levels and hippocampal volume (Figure 3C).
There were no differential associations in age strata or
in APOE 4 strata (data not shown).
Estradiol Level and Memory
When we investigated the relation between estradiol lev-
els and memory performance in men, a similar pattern
as in women emerged. The age-adjusted delayed recall
scores decreased across increasing total estradiol ter-
tiles from 6.1 (0.3) to 5.4 (0.3) to 5.1 (0.3) words. When
we analyzed the total estradiol level as a continuous mea-
sure, we found a decrease in delayed recall with increas-
ing levels (Table 3). Additional adjustments for covari-
ates did not change this association (Figure 3D and Table
3). The association of delayed recall score with bioavail-
able and free estradiol levels showed a similar pattern as
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Figure 3. Adjusted hippocampal volumes (SEs) (A and C) and delayed recall (SEs) (B and D) across tertiles of total, bioavailable and free estradiol levels in women
and men, respectively. A and B, In women means are adjusted for age, educational level, body mass index (calculated as weight in kilograms divided by height in
meters squared), alcohol consumption, smoking, Center for Epidemiologic Studies–Depression Scale score, type of menopause, age at menopause, ever use of
hormone replacement therapy, apolipoprotein E genotype, and the hippocampal volumes–midsagittal area. Tertile ranges (in picograms per milliliter) were for total
estradiol levels 0.0-1.9, 1.9-5.2, and 5.2-17.7; for bioavailable estradiol levels 0.0-1.5, 1.5-3.8, and 3.8-13.4; and for free estradiol levels 0.00-0.05, 0.05-0.14, and
0.14-0.47. Asterisks indicate statistically significantly (P.05) smaller than lowest tertile. C and D, In men means are adjusted for age, educational level, body
mass index, alcohol, smoking, Center for Epidemiologic Studies–Depression Scale score, apolipoprotein E genotype, and the hippocampal volumes–midsagittal
area. Tertile ranges (in picograms per milliliter) were for total estradiol level 0.0-9.8, 9.8-14.2, and 14.2-42.8; for bioavailable estradiol level 0.0-7.4, 7.4-10.9, and
10.9-32.7; and for free estradiol level 0.00-0.26, 0.26-0.41, and 0.41-1.14.
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differences in the associations in age strata or in APOE
4 strata (data not shown).
COMMENT
In this population-based study in elderly subjects with
no dementia, we could not support the hypothesis that
higher endogenous levels of estradiol are associated with
larger hippocampal volumes on MRI and better memory
performance. Women with higher estradiol levels had
smaller hippocampal volumes and poorer memory per-
formance than women with lower levels. In men, there
was no relation between estradiol level and hippocam-
pal volumes, but memory performance was worse in those
with higher levels of total estradiol compared with those
with lower levels.
The strengths of this study are that it is population
based and involves a large number of volumetric hippo-
campal assessments. Our study has several methodologi-
cal limitations that need to be discussed. First, owing to
the small amounts of plasma available, we had a large
number of missing data on bioavailable and free
estradiol levels. Although these missing data were ran-
dom, the smaller sample size will have resulted in less
precise estimates of the associations. Second, blood was
drawn several years before MRI and memory perfor-
mance. It is difficult to determine if this influenced our
results. It may have led to biased associations if subjects
Table 3. Associations Between Total Estradiol Levels and Hippocampal Volumes and Memory Performance*
Women
Per Increase of 1 SD (3.8 pg/mL) in Total Estradiol Level
Hippocampal Volume, mL Delayed Recall, No. of Words
Adjusted for
Age and midsagittal area† −0.01 (−0.12 to 0.10) −0.1 (−0.4 to 0.3)
Age, midsagittal area† and BMI −0.04 (−0.16 to 0.08) −0.1 (−0.5 to 0.3)
Age, midsagittal area,† BMI, education, alcohol consumption,
smoking, CES-D, APOE genotype, age, and type of
menopause, ever use of HRT
−0.06 (−0.18 to 0.06) −0.1 (−0.5 to 0.3)
Men
Per Increase of 1 SD (6.3 pg/mL) in Total Estradiol Level
Hippocampal Volume, mL Delayed Recall, No. of Words
Adjusted for
Age and midsagittal area† 0.02 (−0.10 to 0.15) −0.4 (−0.7 to −0.0)
Age, midsagittal area,† and BMI −0.01 (−0.05 to 0.03) −0.4 (−0.7 to 0.0)
Age, midsagittal area,† BMI, education, alcohol consumption,
smoking, CES-D, and APOE genotype
0.04 (−0.09 to 0.18) −0.3 (−0.7 to 0.1)
Abbreviations: APOE, apolipoprotein E; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CES-D, Center for
Epidemiologic Studies–Depression Scale; HRT, hormone replacement therapy.
*Values are adjusted regression coefficients (95% confidence interval) of the relation between total estradiol level and hippocampal volume/delayed recall
score.
†Values adjusted for only the hippocampal analyses.
Table 4. Associations Between Total Estradiol Levels and Hippocampal Volumes and Memory Performance in Women
According to Apolipoprotein E (APOE) 4 Strata*
Variable
Hippocampal Volumes, mL
P Interaction Term†Non-APOE 4 Carrier APOE 4 Carrier
Adjusted for
Age, midsagittal area, BMI, educational level, alcohol consumption,
smoking, CES-D, age, type of menopause, and ever use of HRT
0.01 (−0.16 to 0.17) −0.25 (−0.46 to −0.03) .07
Delayed Recall, No. of Words
Non-APOE 4 Carrier APOE 4 Carrier
Adjusted for
Age, BMI, educational level, alcohol consumption, smoking,
CES-D, age, type of menopause, and ever use of HRT
−0.10 (−0.61 to 0.41) 0.44 (−0.21 to 1.09) .29
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CES-D, Center for Epidemiologic
Studies–Depression Scale; HRT, hormone replacement therapy.
*Values are adjusted regression coefficients (95% confidence interval) of the relation between total estradiol level (per 1 SD increase) and hippocampal
volume/delayed recall score.
†P value of interaction term (APOE 4 strata  total estradiol level) in the multivariate linear regression analysis.
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with estradiol levels on one side of the distribution
selectively died between blood drawing and MRI mea-
surement. This does not seem likely, however, because
the interval between blood drawing and MRI was not
long, and the relation between endogenous estradiol lev-
els and mortality is not strong.26 Third, HRT use in the
Netherlands is infrequent compared with, for example,
the United States. Our results were based on observa-
tions in non-HRT users and they may not be generaliz-
able to HRT users.
The most consistent support for the hypothesis
that estrogens prevent dementia comes from animal
studies that showed that estrogens protect against cell
loss in the hippocampus, increase neurite outgrowth,
and have antioxidative properties.3,27 In humans, obser-
vational studies on endogenous levels of estrogen in
relation to cognitive function have been inconclusive.
Some reported negative effects of higher endogenous
estrogen levels on delayed visual reproduction28 and
attention tasks29 in women and on the results of the
Mini-Mental State Examination, memory tasks,30 and
spatial performance31 in men, while others showed in
women positive effects of higher endogenous estrogen
levels on verbal memory32 or cognitive decline.33
Population-based studies on exogenous estrogens
showed that women who used HRT had a reduced risk
of AD,1,2,34 but these studies may have been confounded
by healthy-user effect. Also, other studies did not con-
firm this observation.35-37 Recent randomized trials with
HRT in patients with AD showed no38-40 beneficial effect
of exogenous estrogen on cognitive decline.41 Together,
the biological plausibility of the estrogen hypothesis in
dementia is its strongest plea, whereas studies in
humans are far from conclusive. Our results are con-
trary to what we expected in that we observed a small
negative effect of higher estradiol levels on both hippo-
campal volumes in women and memory performance in
women and men. As yet, we do not have a biologically
plausible explanation for these results. When interpret-
ing these data, one has to keep in mind that the endog-
enous levels in our study sample of postmenopausal
women are much lower than the levels obtained after
supplemental use of exogenous estrogens. Therefore,
our data do not reject the possibility that exogenous
estrogens are related to larger hippocampal volumes
and better memory performance.
CONCLUSION
This study does not support the hypothesis that higher
endogenous estrogen levels in older women and men with-
out dementia are associated with larger hippocampal vol-
umes and better memory performance.
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